Lifyorli is a medicine used to treat ovarian cancer that has stopped responding to platinum chemotherapy. It is taken as a capsule by mouth, along with a chemotherapy drug called nab-paclitaxel. It works by blocking the stress hormone cortisol, which can help the chemotherapy work better.
Every report comes from a Lived member, sent anonymously.
Have you tried Lifyorli (Relacorilant) for Ovarian Tumors?
Relacorilant, sold as Lifyorli, is a prescription capsule used together with the chemotherapy drug nab-paclitaxel (a form of paclitaxel given by IV infusion) to treat adults with ovarian, fallopian tube or primary peritoneal cancer that is platinum-resistant. Platinum-resistant means the cancer did not respond to, or stopped responding to, platinum-based chemotherapy such as carboplatin. These three cancers start in closely related tissue and are treated in much the same way. It is meant for people who have already had one to three earlier courses of cancer treatment, at least one of which included bevacizumab, a medicine that slows tumor growth by blocking the blood vessels that feed it. Relacorilant is not used on its own. The FDA approved it in March 2026, and this cancer use is its only approved use in the US. It has also been studied for Cushing syndrome, a condition caused by too much cortisol, but that is not an approved use.
Cortisol is the body's main stress hormone. It acts by attaching to glucocorticoid receptors, switches found on cells throughout the body. In some tumors, cortisol signaling appears to help cancer cells survive chemotherapy that would otherwise kill them, and cortisol also dampens parts of the immune response. Relacorilant is a glucocorticoid receptor antagonist: it sits in those receptors and blocks cortisol from acting, without lowering the amount of cortisol in the blood. In laboratory studies, blocking this signal made paclitaxel kill more tumor cells. In people, the main trial showed that adding relacorilant to nab-paclitaxel helped people live longer than nab-paclitaxel alone. The reason it helps is not fully worked out, and the same cortisol blocking is behind several of its main risks.
Nab-paclitaxel is given as an IV infusion in the clinic once a week for three weeks, followed by a week off, in repeating four-week cycles. Relacorilant is taken by mouth at home on three days around each infusion: the day before, the day of and the day after. The capsules come on blister cards labeled for each dose, and treatment continues as long as it is working and side effects are manageable. Take each dose with food, which helps the body absorb it, and swallow the capsules whole without crushing, chewing, dissolving or splitting them. If a dose is less than 12 hours late, take it; if 12 hours or more have passed, skip it and take the next one on schedule. Do not double up, and do not repeat a dose after vomiting. When the infusion is delayed or stopped, relacorilant is paused too. The nab-paclitaxel dose used in this combination is lower than its usual dose for other cancers, and other forms of paclitaxel should not be substituted.
Most side effects come from the combination rather than relacorilant alone. The most common are lower blood counts (anemia, which can cause tiredness and shortness of breath, low white blood cells and low platelets), fatigue, nausea, diarrhea, rash and loss of appetite. Mouth sores, swelling, nail changes, cough, dizziness and taste changes are also fairly common. In the main trial, about a third of people had a serious side effect, and most needed at least one treatment delay. Low white blood cells (neutropenia) raise the risk of serious, sometimes fatal infection, so blood counts are checked before each weekly treatment. Contact the cancer care team right away about a fever, chills, confusion or other signs of infection. Because relacorilant blocks cortisol, it can cause adrenal insufficiency, a potentially life-threatening shortage of cortisol's effects. It can happen at any point during treatment and is more likely during an illness, infection or surgery. Contact the care team right away about feeling dizzy or lightheaded, low blood pressure, low blood sugar, or weakness, tiredness, nausea, vomiting or appetite loss that is getting worse. Blood cortisol tests cannot reliably detect this problem, so symptoms matter, and treatment often involves higher steroid doses than usual.
Steroid medicines such as prednisone and dexamethasone (glucocorticoids) work through the same receptor that relacorilant blocks. Relacorilant must not be used by anyone who relies on steroids for a lifesaving purpose, such as preventing rejection of a transplanted organ. For people taking steroids for something else, like an autoimmune condition, each medicine can make the other less effective, so the condition may flare. Report any worsening of the other condition, and confirm with the care team whether any medicine you take is a steroid. Relacorilant strongly raises the blood levels of many medicines broken down by a liver enzyme called CYP3A, and some other medicines speed up that enzyme, lowering relacorilant and paclitaxel levels enough to weaken treatment. The care team and pharmacist should review every prescription, over-the-counter medicine and supplement before starting. Its blocking effect can last up to about six days after the last dose, and anyone who has taken it within 30 days of surgery should tell the surgical team, since extra steroids may be needed. It is generally avoided in moderate or severe liver disease. Relacorilant can harm a developing baby. A pregnancy test is done before starting, and effective birth control is needed during treatment and for one week after the last dose, both for women who could become pregnant and for men whose partners could. Tell the care team right away about a known or suspected pregnancy. Breastfeeding should stop during treatment and for one week afterward.
Treatment follows a weekly rhythm built around the infusions, with a blood test before each one and imaging scans every two to three months to see whether the cancer is shrinking, stable or growing. Dose delays are common, mostly because of low white blood cell counts, and some people receive injections that help the bone marrow make white cells. In the main trial, people stayed on relacorilant for a median of about five months. The goal is to control the cancer and extend life rather than cure it. In the main trial, a study of 381 people, those who received relacorilant with nab-paclitaxel lived a median of 16.0 months, compared with 11.9 months for nab-paclitaxel alone, and the cancer was held in check slightly longer (6.5 versus 5.5 months). These are averages, and individual results vary widely. Fatigue and other side effects can add up over the cycles, so it is worth telling the team early when daily life is getting harder, since doses can be adjusted.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lifyorli (Relacorilant), what you've noticed, or ask the community a question.